secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001396814-22-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports July 2022 net product sales of $50.2M; EXPAREL daily sales up 5% YoY
--------------------------------------------------------------------------------

- Preliminary unaudited net product sales for July 2022: $50.2M total ($40.9M EXPAREL, $8.2M ZILRETTA, $1.1M iovera°).
- EXPAREL net sales flat vs. July 2021 at $40.9M, but average daily sales up 5% on 20 vs. 21 selling days.
- ZILRETTA sales of $8.2M reflect continued early-stage growth; iovera° sales $1.1M vs. $1.0M prior year.
- CEO cites expanding EXPAREL adoption; Phase 3 lower extremity nerve block results expected in Q3 and Q4 2022.
- No FY2022 revenue or gross margin guidance provided due to ongoing COVID-19 and labor uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000055/0001396814-22-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000055/pcrx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer